APA (7th ed.) Citation

S, S., A, P., FG, H., P, G., Y, X., AH, P., . . . M, B. (2025). Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison. Dermatology and therapy, 15(9), 2537. https://doi.org/10.1007/s13555-025-01479-y

Chicago Style (17th ed.) Citation

S, Ständer, et al. "Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison." Dermatology and Therapy 15, no. 9 (2025): 2537. https://doi.org/10.1007/s13555-025-01479-y.

MLA (9th ed.) Citation

S, Ständer, et al. "Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison." Dermatology and Therapy, vol. 15, no. 9, 2025, p. 2537, https://doi.org/10.1007/s13555-025-01479-y.